SEC Form 4Coverage since Jun 15, 2026
$OTLC insider trading
Over the last 12 months, Oncotelic Therapeutics insiders reported 4 buys totaling $38K and no sales across SEC Form 4 filings.
- Bought · 12m
- $38K 4 events
- Sold · 12m
- — 0 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $OTLC · 12Mvia TradingView
Top insiders · 12m
Trieu VuongCHAIRMAN AND CEO3× · $37K
Shah Amit B.CFO1× · $1K
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 1, 2026 | Trieu VuongCHAIRMAN AND CEO · O·D·10% | ▲ Buy | 240,000 | $0.04 | $10K | +0.3% | — |
| Jun 24, 2026 | Trieu VuongCHAIRMAN AND CEO · O·D·10% | ▲ Buy | 255,000 | $0.04 | $11K | +0.3% | 3 tranches |
| Jun 22, 2026 | Shah Amit B.CFO · O | ▲ Buy | 20,000 | $0.05 | $1K | +5.6% | — |
| Jun 17, 2026 | Trieu VuongCHAIRMAN AND CEO · O·D·10% | ▲ Buy | 335,759 | $0.04 | $15K | +0.4% | 2 tranches |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $OTLC feed.